Sub-Population Optimization Solutions

When Phase II or III studies demonstrate sub-optimal outcomes or result in failure, assets can be de-prioritized or abandoned, which impacts patient populations who could greatly benefit from the treatment. IQVIA™ pairs end-to-end clinical development expertise with artificial intelligence / machine learning to drive an innovative analytical approach to identifying predictive sub-groups and biomarkers in clinical and real-world data.

Read our factsheet to learn how to:

  • Increase the probability of rescuing a failing asset
  • Redesign trial or enable an add-on study
  • Improve design of next phase trials
  • Adapt regulatory strategy for a completed study
  • Manage your asset pipeline for predictable return on investment

Please complete the following form to download the factsheet

Copyright © 2023 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement

DO NOT SELL MY PERSONAL INFORMATION